earnings

$AMGN Amgen reported a loss in the fourth quarter of 2017 due to the inclusion of a $6.1 billion charge related to the impacts of the U.S. corporate tax reform. The results came in below analysts expectations. In addition, the company issued guidance for the year 2018, which remained in line...

Eli Lilly reports an increase in pharma sales and decline in Animal Health. Lifts 2018 earnings outlook. When answering an analyst question, Enrique Conterno said, "We continue to see pressure on pricing across all of our diabetes products".

http://alph.st/ba8b5da2 Tremendous Spinraza/biosimilars growth numbers

http://alph.st/ba1df6ff Higher sales of Revlimid and Otezla help Celgene to report better than expected sales figure. Will the two (Impact and Juno) multi-billion dollar acquisitions help the struggling Celgene in 2018 and beyond?

Medical equipment producer $CMD reported a 22% rise in its 1Q18 profit, helped by increased sales. Net income rose to $22.9MM, or $0.55 per share, from $18.8MM, or $0.45 per share during 1Q17. Adj. EPS was $0.57, up 12.7%. Total sales rose 22% YoY to $212.7MM, helped by organic growth of 8.6%...

Non-cash goodwill and asset impairment charges in the DMG reportable segment hurt DaVita's Q3 2017 results. Total U.S. dialysis treatments for 3Q17 were 7.2 million. As of Sept. 30, 2017, DaVita provided dialysis services to a total of about 218,200 patients. Graphical view of results...

Valeant posted a quarterly profit helped by the strong performance of its Bausch and Lomb Business. Net income attributable to Valeant rose to $1.30Bil, or $3.69 per share, during the quarter , compared with a loss of $1.22Bil, or $3.49 per share, a year earlier. Total revenue fell 10.5% to...

Cardinal Health (CAH) earnings for the first quarter of 2018 are hurt by restructuring costs from regaining direct distribution of self-manufactured surgeon gloves and higher intangible assets amortization. Despite this, the company reaffirmed its full-year 2018 non-GAAP EPS guidance. Graphical...

In the third quarter, even as revenue jumped 7%, net earnings came crashing down by about 30%. Even their safely adjusted EPS fell 3%. It's been an up-and-down kind of year for Bristol-Myers Squibb. Early this year, we investors were concerned after BMY opted not to pursue accelerated approval...

Allergan swings to quarterly loss on charges related to Restasis and Teva holding. Given the Federal Court's decision, plans to mitigate the financial impact of generic competition http://alph.st/b68181eb

GILD revenue down 13%; profit down 18%; product sales down 14%. Poor sales of hepatitis C drugs with lower sales predicted for the year. Hope the $12 bln acqusition of Kite Pharma should help the company.

http://alphastreet.com/b0662389 Celgene's outlook, especially it's long-term targets, is not an encouraging one. Also, a decrease in pharma company's research and development expenses is not a good sign.

https://alphastreet.com/bite/d578727 Amgen, that is in the process of refreshing its product portfolio, reported higher-than-expected 3Q profit, but sales declined in some of its biggest established products.

https://alphastreet.com/bite/d578727 Amgen, that is in the process of refreshing their product portfolios, reported higher-than-expected 3Q profit, but sales declined in some of its biggest established products.

Lower costs and expenses aid in a jump in 3Q17 earnings of Baxter. The company posted net income of $251MM or $0.45 per share, on sales of $2.71Bil. Global sales for Hospital Products grew 7% on continued strength in U.S. fluid systems business as well as favorable demand for injectable...

Lilly reports third quarter 2017 results. Lowers 2017 reported EPS outlook. Plans to sell or spin off Elanco Animal Health. Check out this earnings infograph http://alph.st/be0ed58e

Medtronic posted a 9.4% YoY increase in profit to $1.02 bln, or $0.74 per share, for the first quarter of 2018. The company generated most of its sales from heart devices, spinal implants and insulin pumps, resulting in a 3.1% growth in revenue to $7.4 bln. Earnings Infographic...

Apparently, Soliris drug sales are increasing. https://alphastreet.com/bite/4dac307 But how long can this company run on this? Given, the company has also announced that it is reducing the R&D expense for the year.

$PG Procter & Gamble Earnings AlphaGraphic: Q4 2017 Highlights

$VRTX Vertex's cystic fibrosis portfolio progression has led the company to increase its guidance of combined R&D and SG&A for the full year 2017.